CRA is a proud sponsor and exhibitor of this event.
Andy Parece and Matt Majewski are presenting their study on the topic of “New Findings: US-based payer, physician and patient input on fair pricing”.
For more information on this event, click here.
Paving the way for expanded GLP-1 coverage
GLP-1 agonists were originally approved to treat Type 2 Diabetes (T2D) – but their most recent incarnations, which consist of both next generation GLP-1s and...